Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart safety check for promising sickle cell drug

NCT ID NCT07023029

First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 36 times

Summary

This study checks whether etavopivat, a new medicine for sickle cell disease and thalassemia, changes the heart's electrical activity. It involves 33 healthy adults who receive different doses of the drug, a placebo, or an approved heart medication. The goal is to ensure the drug is safe for the heart before moving to larger patient studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • PAREXEL Intl - EPCU-Baltimore

    Baltimore, Maryland, 21225, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Etavopivat

What this could lead to

If successful, this study will confirm that etavopivat is safe for the heart, supporting its further testing as a potential treatment for sickle cell disease and thalassemia.

What could go wrong

This is an early phase 1 study in only 33 healthy people, not patients. It only looks at heart safety, not whether the drug works for the disease. Results may not predict effects in patients.

Conditions

The condition(s) this trial relates to.

sickle cell disease thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.